<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">Interestingly, interleukin(IL)-6 levels are significantly elevated in severe COVID-19, suggesting its crucial role in cytokine storm and predicting adverse outcomes [
 <xref ref-type="bibr" rid="CR13">13</xref>, 
 <xref ref-type="bibr" rid="CR14">14</xref>]. IL-6 levels are associated with SARS-CoV-2 viral load [
 <xref ref-type="bibr" rid="CR15">15</xref>]. Blocking IL-6 receptor might be a promising strategy in the disease management. Preliminary evidence from a small uncontrolled trial in China proves that tocilizumab in addition to routine therapy is effective for decreasing C-reactive protein levels and alleviating symptoms. Tocilizumab therapy is listed in the recommendations for severe COVID-19 management by the National Institute for the Infectious Diseases ‘Lazzaro Spallanzani' [
 <xref ref-type="bibr" rid="CR5">5</xref>].
</p>
